Interpace Biosciences – Consensus Indicates Potential 212.6% Upside

Broker Ratings

Interpace Biosciences with ticker code (IDXG) now have 4 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 20 and 7 calculating the mean target price we have 12.13. Now with the previous closing price of 3.88 this now indicates there is a potential upside of 212.6%. The day 50 moving average is 3.4 and the 200 day moving average is 3.91. The company has a market cap of $16m. Find out more information at: http://www.wearepdi.com

Interpace Biosciences provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group and changed its name to Interpace Biosciences in November 2019. Interpace Biosciences was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

AIM All Share Index